Vimarsana
Biggest News Aggregation in the World

Concern Delta News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Concern Delta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Concern Delta Today - Breaking & Trending Today

Variant of Concern (VOC) Delta to Omicron, Transmissibility, Severity, Impact of Social Mobility - What will drive future trends and Optimizing our response - PAHO/WHO - Vimarsana News

Variant of Concern (VOC) Delta to Omicron, Transmissibility, Severity, Impact of Social Mobility - What will drive future trends and Optimizing our response - PAHO/WHO

The PAHO/WHO Office for Barbados and the Eastern Caribbean Countries will be hosting a webinar on the factors that will continue to drive Covid-19 surges and potential impact of the Variant of Concern Delta and Omicron SARS-CoV-2. Objectives

Source: paho.org
Researchers identify a molecular culprit for COVID-19's seasonal nature - Vimarsana News

Researchers identify a molecular culprit for COVID-19's seasonal nature

Not to pile on, but winter is coming and the COVID-19 pandemic is about to get worse. Not necessarily because of omicron – scientists are still working that one out – but because there’s more evidence than ever that COVID-19 is a seasonal disease.

Alphagalileo > Item Display - Vimarsana News

Alphagalileo > Item Display

Not to pile on, but winter is coming and the COVID-19 pandemic is about to get worse. Not necessarily because of omicron – scientists are still workin....

Phase I clinical study evaluates safety and pharmacokinetics of ExeVir's COVID-19 neutralizing antibody - Vimarsana News

Phase I clinical study evaluates safety and pharmacokinetics of ExeVir's COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody - Vimarsana News

ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody

/PRNewswire/ -- ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the...